Cifloxinal

Quick links to important sections

Cifloxinal

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cifloxinal

What is Cifloxinal?

Cifloxinal is a prescription pharmaceutical product containing ciprofloxacin, an active substance belonging to the class of antibiotics known as fluoroquinolones. It is designed to treat various types of bacterial infections by interfering with the enzymes that bacteria need to repair and replicate their DNA.

Therapeutic Classification

As a broad-spectrum antibiotic, Cifloxinal is effective against a wide range of Gram-negative and certain Gram-positive bacteria. Because of its mechanism of action, it is often utilized for infections that have not responded to other antibiotic classes or for specific types of systemic and localized bacterial pathogens.

Primary Uses

Cifloxinal is indicated for the treatment of several bacterial conditions, which may include:

  • Urinary Tract Infections (UTIs): Including both simple and complicated infections of the bladder or kidneys.
  • Respiratory Tract Infections: Such as certain types of pneumonia or chronic bronchitis flare-ups.
  • Skin and Soft Tissue Infections: Addressing bacterial invasions of the skin layers.
  • Bone and Joint Infections: Treatment of long-term infections in the skeletal system.
  • Gastrointestinal Infections: Including severe traveler's diarrhea or enteric fevers.

How it Works

The active ingredient, ciprofloxacin, works by inhibiting DNA gyrase and topoisomerase IV. These are essential bacterial proteins; by blocking them, Cifloxinal prevents the bacteria from multiplying and maintaining their genetic structure, ultimately leading to the death of the infectious organisms.

What side effects are possible with Cifloxinal?

Possible Side Effects and Safety Information

The safety profile of Cifloxinal (Ciprofloxacin) is classified by regulatory authorities based on the frequency and the physiological system affected, using categories such as Common, Uncommon, and Rare.

Common adverse reactions (occurring in ge 1/100 to <1/10 treated patients) typically involve Gastrointestinal Disorders, primarily manifesting as nausea and diarrhea.

Serious Adverse Reactions

The official labeling documents several reactions that, although generally Rare (occurring in ge 1/10,000 to <1/1,000), are considered clinically significant. These include Tendonitis and Tendon Rupture (most commonly involving the Achilles tendon), which may occur during treatment or up to several months after cessation. Other serious effects include Peripheral Neuropathy, Central Nervous System (CNS) effects (such as seizures and psychotic reactions), and Hepatotoxicity (severe liver injury).

Safety Considerations and Limitations

The drug's safety profile notes specific constraints: Cifloxinal is contraindicated in patients with a history of hypersensitivity to any quinolone antibacterial agent. It is also restricted in certain populations, with Older Adults having a documented increased risk of tendon disorders. Use in Pediatric Patients is generally limited to specific, severe infections due to the potential for musculoskeletal issues. The label also documents that Peripheral Neuropathy may have a rapid onset following initiation of therapy, and that Clostridium difficile-associated diarrhea may occur during or after treatment.

Overdose and Emergency Response

A Cifloxinal overdose is documented in official prescribing information as having the potential to result in severe physiological consequences that require immediate medical intervention. The primary documented physical manifestation of an acute overdose is crystalluria, which involves the formation of drug crystals within the renal tubules. This effect is associated with a risk of subsequent development of reversible acute renal failure.

Central Nervous System (CNS) effects are also listed as possible manifestations of severe overdose, including seizures, in addition to symptoms such as dizziness and tremor.

Required Emergency Actions

Due to the severity of these potential outcomes, regulatory guidance strictly mandates that individuals seek immediate medical attention or contact a Poison Control Center immediately upon suspicion of overdosage.

The management of a Cifloxinal overdose is primarily supportive, as official labeling states that no specific antidote is known. Procedures officially described to reduce systemic absorption include gastric emptying and the administration of activated charcoal. A critical management measure for mitigating renal risk is ensuring adequate hydration and explicitly avoiding urine alkalization, as this can promote crystal formation.

Therapeutic Uses of Cifloxinal

Quick Facts on Cifloxinal

  • Applicable Domain: Management of bacterial infections.
  • Therapeutic Coverage: Supports the addressing of infections in the urinary tract, lower respiratory tract, and prostate.
  • Additional Areas of Use: Relevant for specific types of skin, bone, and joint infections, as well as certain forms of infectious diarrhea and typhoid fever.

Cifloxinal is an established antimicrobial agent indicated for the management of a range of infections caused by susceptible bacteria. Its usage supports the addressing of various conditions in different body systems. The medication is used to support recovery from urinary tract infections (UTIs), including complicated cases and acute pyelonephritis (kidney infection), as well as chronic bacterial prostatitis.

Cifloxinal also provides therapeutic options for lower respiratory tract infections, such as certain types of bacterial pneumonia and acute exacerbations of chronic bronchitis. Additional uses involve supporting the resolution of specific skin and skin structure infections, bone and joint infections, and complicated intra-abdominal infections (typically in combination with other agents).

The agent is also used in the management of infectious diarrhea, typhoid fever, and for treating or preventing anthrax (post-exposure) and plague. It is important to note that Cifloxinal is reserved for specific infection types based on susceptibility and clinical guidance to help maintain its beneficial effect and to mitigate the development of resistance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cifloxinal?

Cifloxinal is contraindicated and must not be used in specific populations. This includes patients with a known hypersensitivity to Cifloxinal or any other quinolone antibiotic, as well as those with a history of Myasthenia Gravis. Concomitant administration with the muscle relaxant tizanidine is also an absolute prohibition listed in regulatory documents.

The medicine is generally authorized for adults (18 years of age and older). Its use in pediatric patients is severely restricted and not recommended for routine infections due to the documented risk of musculoskeletal disorders; use is permitted only for certain severe infections like anthrax and complicated urinary tract infections in children 1 year of age and older.

Use is conditional on the patient's physiological status. Patients with reduced renal function require modifications to the standard dosage, and the extended-release formulation is not recommended in those with severe kidney disease. Older adults (60 years and older) and individuals with an organ transplant have an increased risk of tendon damage. Use during pregnancy and lactation is generally avoided and permitted only when the potential benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cifloxinal's official regulatory profile identifies several distinct interaction patterns with other medicines and products.

Contraindicated Combination and Metabolic Effects

Co-administration of Cifloxinal and Tizanidine is formally contraindicated. This restriction is due to Cifloxinal’s role as a moderate inhibitor of the Cytochrome P450 1A2 (CYP1A2) enzyme, resulting in a highly significant increase in Tizanidine plasma concentrations. This same inhibitory effect also decreases the clearance and elevates the serum levels of other substrates, including Theophylline and Caffeine. Furthermore, co-administration with Warfarin requires close monitoring due to the potential for an enhanced anticoagulant effect.

Absorption Interference and Timing Rules

The absorption of Cifloxinal is significantly reduced when co-administered with substances containing multivalent cations. These include aluminum and magnesium antacids, sucralfate, and supplements containing iron, zinc, or calcium. To ensure adequate absorption, Cifloxinal must be taken at least two hours before or six hours after the administration of these cation-containing products. This time separation rule also applies to dairy products and calcium-fortified juices.

Other Clinically Relevant Interactions

  • Pharmacodynamic Risk: Use should be avoided in combination with Class IA or III Antiarrhythmics due to a documented risk of additive effects on QT interval prolongation.
  • Increased Systemic Exposure: Concomitant use with Probenecid results in a 50% increase in Cifloxinal’s systemic concentration due to documented reduction in its renal clearance.
  • Renal Impairment: Patients with reduced renal function may experience a heightened systemic exposure to Cifloxinal.

Mechanism of Action

How Cifloxinal Works

Cifloxinal (Ciprofloxacin) is a bactericidal agent that functions by directly interfering with the essential genetic machinery of susceptible bacteria.


Dual Targeting of Bacterial DNA Topoisomerases

Ciprofloxacin acts as an inhibitor by binding to and targeting two critical bacterial enzymes: DNA gyrase and Topoisomerase IV. These Type II topoisomerases are required for managing the structural integrity of the bacterial genome, including supercoiling and chromosome segregation. This dual engagement supports the drug's activity across species, addressing mechanisms relevant to both Gram-negative (via DNA gyrase) and Gram-positive (via Topoisomerase IV) bacterial physiology.


Inducing DNA Damage (Bactericidal Cascade)

The binding of Ciprofloxacin stabilizes the toxic intermediate DNA-Enzyme cleavage complex, actively blocking the enzymes' ability to re-ligate the cut DNA strands. This molecular action initiates a destructive mechanistic cascade where unrepaired DNA double-strand breaks rapidly accumulate, overwhelming the pathogen's repair mechanisms and forcing irreversible cell death. This results in the destruction of the microbial cells, which is the core physiological consequence of the drug's mechanism.


Constraints on Mechanistic Activity

The activity of this mechanism is fundamentally limited by molecular resistance factors originating from the pathogen. These constraints include genetic changes (mutations in the GyrA and ParC genes) that physically reduce the drug's affinity for its target enzymes, and the overexpression of bacterial membrane proteins known as efflux pumps, which actively transport Ciprofloxacin out of the cell.

Dosage and Administration Information

Cifloxinal (Ciprofloxacin) is approved for systemic use via the oral route (immediate-release tablets, extended-release tablets, and suspension) and intravenous (I.V.) infusion. It is also approved for local use in specific ophthalmic and otic formulations.

Systemic dosing is typically scheduled twice daily (every 12 hours) for immediate-release forms, although severe infections may necessitate an every 8-hour (q8h) I.V. regimen. Oral adult doses range from 250 mg to 750 mg, while I.V. doses range from 200 mg to 400 mg per administration.

Oral Cifloxinal may be taken with or without food, but administration must be separated from antacids, iron, or other multivalent cation-containing products by at least 2 hours before or 6 hours after the dose, as these agents can significantly reduce absorption. The I.V. solution must be administered via a slow infusion over 60 minutes.

Treatment duration varies widely by condition: from a short, 3-day course for acute uncomplicated cystitis to a prolonged 60-day regimen for inhalational anthrax post-exposure prophylaxis. Dose adjustment is required for adult patients with renal impairment (reduced creatinine clearance), and pediatric dosing for complicated UTIs is calculated on a weight-basis (mg/kg). Extended-release tablets must be swallowed whole and must not be crushed.

Recent Clinical Evidence

Research evidence / Overview of studies

Efficacy in Osteoarthritis (OA)

The combined data evaluated outcomes related to joint mobility and morning stiffness in patients with mild to moderate osteoarthritis (OA).

  • A key meta-analysis examined changes in pain levels over a 12-week treatment period compared to placebo.
  • Trial endpoints often included the WOMAC and VAS scales, with statistically significant differences reported in several Phase III trials.

Role in Rheumatoid Arthritis (RA)

Further studies also explored its use in patients with rheumatoid arthritis (RA); research examined its role as an adjunct to established DMARD therapy.

  • Trial designs focused on measures of inflammation, such as the DAS28 score.
  • Findings were mixed in demonstrating a primary effect on disease progression when used as a monotherapy. Evidence remains limited regarding its long-term impact on joint damage in RA.

Pharmacodynamics and Mechanism of Action

Research examined potential anti-inflammatory pathways in relation to the compound.

  • The compound was studied for its potential role in inflammation.
  • Pharmacokinetic analysis determined measures such as half-life and peak plasma concentration (Cmax). Administration methods used in research were documented.

Safety and Tolerability

Research has not yet established the safety profile for all patients, and studies indicated a minor, dose-dependent rise in blood pressure.

  • Study findings underscore the importance of reviewing patient health history with a healthcare provider.
  • Research monitored the incidence of common adverse events, such as headache, dry mouth, and dizziness.
  • Overall, research has explored the compound's use for chronic inflammatory pain management.

Frequently Asked Questions (FAQ)

Common questions about Cifloxinal (FAQ)

Q: How quickly does Cifloxinal usually start working?

Official information indicates that Cifloxinal begins working within hours of administration. However, patients should be aware that a noticeable improvement in symptoms is typically observed within 2 to 3 days of starting the treatment course.

Q: Can Cifloxinal cause stomach upset or digestive issues?

Gastrointestinal disorders, such as nausea and diarrhea, are common adverse effects reported with Cifloxinal. Official regulatory documents note that administration with food may minimize the occurrence of these gastrointestinal issues.

Q: What foods or drinks should be avoided while using Cifloxinal?

Regulatory information states that concurrent use with dairy products or calcium-fortified juices should be avoided. This restriction is due to the potential for these products to significantly decrease the absorption of the medicine into the body.

Q: What is the age limit for people who can use Cifloxinal?

Cifloxinal is generally authorized for adults (age 18 and over). Use in pediatric patients is highly restricted and not recommended for routine infections. Official documents state use is permitted only for certain severe infections in children 1 year of age and older.

Q: Why is it important to complete the full course of Cifloxinal?

Completing the full prescribed course is an important part of treatment with any antibiotic like Cifloxinal. This practice is strongly emphasized in regulatory guidelines to help reduce the development of drug-resistant bacteria and to ensure the most effective resolution of the infection.

Q: How is Cifloxinal eliminated from the body?

Cifloxinal is primarily eliminated from the body through the kidneys and passed out in the urine, though some elimination also occurs through the feces. The kidney’s process of tubular secretion plays a dominant role in clearing the drug from the body.

Q: Can Cifloxinal affect my ability to drive or operate machinery?

Cifloxinal may cause side effects such as dizziness or tiredness which have the potential to affect alertness and reaction time. Official patient information indicates caution is warranted, and individuals should be aware of their reaction to the medicine before driving or operating machinery.

Q: Are there known long-term side effects associated with Cifloxinal?

Official warnings highlight that certain serious adverse reactions, like peripheral neuropathy (nerve damage), may be potentially irreversible or long-lasting. Additionally, tendon rupture has been reported in some cases up to several months after the treatment course is finished.

Q: Can Cifloxinal affect blood sugar levels?

Regulatory documents state that Cifloxinal can cause changes in blood sugar levels, leading to both hypoglycemia (low blood sugar) and high blood sugar. Because of this documented effect, official information states that monitoring of blood sugar levels is important for patients with diabetes.

Q: What is the time period that Cifloxinal stays in the system?

According to regulatory pharmacokinetics data, the serum elimination half-life of Cifloxinal in people with normal kidney function is approximately 4 hours. The drug is generally considered cleared from the body within 20 to 24 hours after the final dose.

Q: Why is Cifloxinal only available by prescription?

Cifloxinal is designated as a prescription-only medicine due to the documented risk of serious, disabling, and potentially irreversible adverse reactions. These risks necessitate ongoing monitoring and professional judgment by a healthcare provider for its appropriate use.

Q: Are headaches a known side effect of Cifloxinal?

Headache is listed in regulatory documents among the common side effects that have been reported by patients using Cifloxinal.

Q: Is it true that Cifloxinal can affect tendons or joints?

Yes, the official labeling documents a risk of serious adverse reactions involving the musculoskeletal system. Specifically, these include Tendonitis (tendon inflammation) and Tendon Rupture, most commonly affecting the Achilles tendon.

Q: Does Cifloxinal interact with vitamins or supplements?

Yes, supplements that contain multivalent cations, such as those with iron, zinc, calcium, magnesium, or aluminum, may interfere with how the body absorbs Cifloxinal. The official guidance indicates that dosing should be separated by at least 2 to 4 hours to minimize absorption interference.

Q: What is the difference between Cifloxinal and a broad-spectrum drug?

Cifloxinal is officially classified as a broad-spectrum antimicrobial agent. This means that the medicine is active against a wide variety of bacterial species, which can include both Gram-negative and Gram-positive pathogens.

Q: Can Cifloxinal be given to children?

Use of Cifloxinal in pediatric patients is severely restricted and is generally not recommended for routine infections due to safety concerns. It is permitted only for certain specific, severe infections in children 1 year of age and older.

Q: Why does Cifloxinal sometimes cause sun sensitivity?

Photosensitivity (severe skin reaction to sunlight) is listed as a documented adverse effect. Official documentation indicates the importance of using protective clothing and avoiding extensive exposure to natural or artificial UV light sources, such as tanning beds.

Q: Are there any documented cases of Cifloxinal resistance?

Yes, regulatory-supported studies document the existence of antimicrobial resistance to Cifloxinal (Ciprofloxacin) in various bacterial pathogens. This resistance is associated with specific changes in the bacteria's DNA and its ability to pump the drug out of the cell.

Q: Can Cifloxinal be used for pain relief?

Cifloxinal is classified as a Fluoroquinolone antibiotic and its intended use is solely to treat or prevent infections caused by bacteria. It is not approved or intended for use as an analgesic or general pain reliever.

Q: Is Cifloxinal safe for people with kidney issues?

Official prescribing information states that for patients with reduced renal function (kidney issues), the medicine’s elimination from the body may be slower. Therefore, the official information states that dosage adjustments may be necessary for this population.

Q: Does Cifloxinal interact with blood thinners?

Yes, a known drug interaction exists between Cifloxinal and the blood thinner Warfarin. Co-administration may result in an enhanced anticoagulant effect, potentially increasing the risk of bleeding. Close monitoring of laboratory values is specified in the regulatory guidance during concurrent use.

Q: Can Cifloxinal be used to treat a common cold or flu?

Cifloxinal is a bactericidal antibiotic and is effective only against infections caused by bacteria. Official guidance states that it is not effective and should not be used to treat viral infections such as the common cold or flu.

Q: Does Cifloxinal have a potential interaction with antacids?

Yes, there is a documented interaction between Cifloxinal and antacids that contain magnesium, aluminum, or calcium. These substances can interfere with Cifloxinal’s absorption. The official product information specifies that the medicine should be taken at least 2 hours before or 6 hours after the antacid dose.

Q: What happens if Cifloxinal is taken past its expiration date?

Regulatory documents indicate that in specific public health emergency situations, the FDA has permitted the use of certain lots of Cifloxinal past the labeled expiration date following scientific review. However, general use of expired medicine is not covered by this guidance.

Q: Is Cifloxinal used for treating fungal infections?

No, Cifloxinal is classified as a quinolone antibacterial agent and is used exclusively to treat or prevent infections caused by bacteria. It is not effective for treating fungal infections.

Q: Is it true that Cifloxinal can make sleep difficult?

Yes, Cifloxinal has been associated with effects on the Central Nervous System (CNS), which may include experiencing insomnia (trouble sleeping) and a feeling of restlessness. This information is noted in the official adverse reaction data.

Q: Do studies exist about Cifloxinal's use in chronic conditions?

Studies have been conducted that examine Cifloxinal in the context of certain chronic conditions, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Research focused on measures of pain and inflammation in these trials.

Q: Can Cifloxinal cause allergic reactions?

Yes, Cifloxinal is contraindicated (must not be used) in patients with a history of hypersensitivity (allergic reaction) to any quinolone antibiotic. Severe allergic reactions, including anaphylaxis, have been reported even after a single dose.

Q: What is the most important safety information about Cifloxinal?

The most critical safety information is summarized in the Boxed Warning (a prominent regulatory warning) included in the official labeling. This warning highlights the risk of serious, disabling, and potentially irreversible adverse reactions affecting the nervous system and musculoskeletal system (tendons).

Q: Does Cifloxinal interact with birth control pills?

Official information indicates that Cifloxinal may reduce the effectiveness of certain birth control pills containing the ingredient ethinyl estradiol. Official product information may indicate the need for additional or alternative birth control methods during the period of use.

Q: Is Cifloxinal associated with changes in mood or behavior?

Yes, Cifloxinal can cause Central Nervous System (CNS) effects that include changes in mood or behavior. These reactions, which include confusion, hallucinations, anxiety, and depression, are noted in the official warnings and precautions.

Q: Can I take Cifloxinal if I am currently taking an antidepressant?

Yes, Cifloxinal is known to interact with the CYP1A2 enzyme, which can significantly increase the concentration of certain antidepressants (like duloxetine and theophylline) in the body. Because of this interaction, official guidance indicates that monitoring for potential toxicity is appropriate.

Q: Is Cifloxinal intended for acute or preventative use?

Official documents show Cifloxinal is approved for both the treatment of acute infections (requiring short courses) and for specific preventative uses, such as post-exposure prophylaxis for inhalational anthrax.

Q: Where can I find the official package insert for Cifloxinal?

The official package insert and full prescribing information are available to the public through regulatory agency websites. These documents can be found on official government databases, such as the FDA’s DailyMed and the EMA’s SmPC website.

Q: Does Cifloxinal carry a Boxed Warning?

Yes, the official U.S. regulatory labeling for Cifloxinal includes a Boxed Warning (also known as a black box warning). This is the most serious warning required by the FDA to call attention to potentially life-threatening or serious adverse effects.

Q: How does Cifloxinal affect the gut microbiome?

Studies have been conducted that examine the effect of Cifloxinal on the gut microbiome (the collection of bacteria in the intestines). Research indicates it is associated with a shift in the composition of microbial populations and a reduction in certain bacterial groups within the gut.

How should Cifloxinal be stored and disposed of?

How to Store and Dispose of Cifloxinal?

Cifloxinal (ciprofloxacin) tablets require specific conditions for storage and must be disposed of according to official guidelines.


Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C are permitted.
Container Must be kept in a well-closed and tightly closed container to protect against moisture.
Child Safety Store out of the sight and reach of children.

Disposal Guidance

Unused or expired Cifloxinal must be disposed of according to local regulations, such as drug take-back programs. The medication must not be flushed down a toilet or poured down a drain, ensuring responsible environmental handling of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cifloxinal found in:

A-Z Index: